Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-Β

Cancer Gene Therapy

Volumn 19, Issue 7, 2012, Pages 443-450

  Naik, S ^a   Nace, R ^a   Barber, G N ^b   Russell, S J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

myeloma; oncolytic; systemic; vesicular stomatitis virus; virotherapy

Indexed keywords

BETA INTERFERON; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SPECIFIC SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; VESICULAR STOMATITIS VIRUS;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HUMANS; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VESICULAR STOMATITIS INDIANA VIRUS;

MURINAE; MUS; VESICULAR STOMATITIS VIRUS;

EID: 84863722111     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.14     Document Type: Article

References (37)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
2. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23: 2222-2232.
3. Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 2004; 17: 516-527. (Pubitemid 40054231)
4. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999; 73: 3723-3732. (Pubitemid 29189814)
5. Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 2010; 21: 451-462.
6. Bi Z, Barna M, Komatsu T, Reiss CS. Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 1995; 69: 6466-6472.
7. Chiocca EA. The host response to cancer virotherapy. Curr Opin Mol Ther 2008; 10: 38-45. (Pubitemid 351170593)
8. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009; 9: 1163-1176.
9. Conzelmann KK. Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses. J Virol 2005; 79: 5241-5248.
10. Platanias LC, Uddin S, Domanski P, Colamonici OR. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. J Biol Chem 1996; 271: 23-23.
11. von Kobbe C, van Deursen JM, Rodrigues JP, Sitterlin D, Bachi A, Wu X et al. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell 2000; 6: 1243-1252.
12. Petersen JM, Her LS, Varvel V, Lund E, Dahlberg JE. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 2000; 20: 8590-8601.
13. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275. (Pubitemid 37329791)
14. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003; 77: 8843-8856. (Pubitemid 36936096)
15. Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007; 6: 1701-1708. (Pubitemid 46954046)
16. Wu L, Huang TG, Meseck M, Altomonte J, Ebert O, Shinozaki K et al. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther 2008; 19: 635-647. (Pubitemid 351913526)
17. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007; 110: 2342-2350. (Pubitemid 47523154)
18. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-893. (Pubitemid 47001642)
19. Alexanian R, Weber D. Whither interferon for myeloma and other hematologic malignancies? Ann Intern Med 1996; 124: 264-265. (Pubitemid 26026012)
20. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994; 84: 4142-4150. (Pubitemid 24371916)
21. Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001; 61: 6201-6212. (Pubitemid 32762558)
22. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4: e353.
23. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010; 17: 550-558.
24. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009; 69: 7713-7720.
25. Whelan SP, Ball LA, Barr JN, Wertz GT. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 1995; 92: 8388-8392.
26. Gobet R, Cerny A, Ruedi E, Hengartner H, Zinkernagel RM. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp Cell Biol 1988; 56: 175-180. (Pubitemid 18260941)
27. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD et al. Carrier cellbased delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007; 15: 123-130. (Pubitemid 46043657)
28. Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol 2010; 84: 7513-7522.
29. Huneycutt BS, Bi Z, Aoki CJ, Reiss CS. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol 1993; 67: 6698-6706. (Pubitemid 23309138)
30. Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Therapy 2007; 14: 638-647. (Pubitemid 46585623)
31. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-ofconcept and future directions. Cancer Res 2007; 67: 429-432. (Pubitemid 46192175)
32. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-333. (Pubitemid 47016683)
33. Kaur B, Cripe TP, Chiocca EA. 'Buy one get one free': armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009; 9: 341-355.
34. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286: 2156-2159. (Pubitemid 129516290)
35. Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011; 19: 650-657.
36. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-937. (Pubitemid 37328894)
37. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001; 75: 3474-3479. (Pubitemid 32225911)